Choline Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Choline dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Choline.
Dosing Protocols
The Beginner Protocol addresses the most common choline scenario: closing the gap between the AI and typical American intake. Roughly 90% of Americans do not meet the choline AI (550 mg men, 425 mg women), and the easiest approach is dietary: 1–2 whole eggs per day (one large egg yolk contains ~147 mg choline), 3–4 oz beef liver weekly (~355 mg per 3 oz), regular fatty fish consumption (salmon, cod ~120 mg per 3 oz), and soy-based foods (tofu, soybeans ~100 mg per cup cooked). If dietary intake is limited (vegetarians, vegans, egg-avoidant), supplementation with 250–500 mg/day choline bitartrate or sunflower lecithin providing equivalent choline is reasonable. For pregnancy, aim for 450 mg/day AI minimum with food plus a prenatal — since most prenatals contain little or no choline, adding a standalone choline supplement providing 250–450 mg/day during pregnancy is reasonable. The Caudill 2018 trial suggests benefit at 930 mg/day, so 450–900 mg/day during pregnancy is within the evidence-supported range. For lactation, continue 550 mg/day. For healthy adults, a standard B-complex often contains 10–55 mg choline which is inadequate; a standalone choline supplement is usually needed if dietary choline is inadequate. Take choline with or without food; absorption is good either way. Start at the lower end (250 mg/day) and titrate up over weeks to assess tolerance. Most healthy adults tolerate up to 500–1,000 mg/day without GI issues. Going above 1,500 mg/day often produces fishy odor from gut bacterial TMA production — this is the dose-limiting side effect for most users. The Beginner Protocol specifically does NOT include Alpha-GPC or CDP-choline at premium prices unless there's a specific cognitive indication — choline bitartrate or sunflower lecithin provide adequate choline for structural and methylation roles at substantially lower cost.
The Intermediate Protocol covers specific indications: pregnancy choline optimization, NAFLD in choline-deficient patients, cognitive enhancement trials, and homocysteine lowering via betaine. For pregnancy fetal neurodevelopment based on Caudill 2018, consider 930 mg/day choline (450 mg from diet + 480 mg as supplement, or 900 mg as supplement if dietary choline is limited) through the third trimester. Evidence suggests benefits for infant information processing speed at 4–13 months. For NAFLD with confirmed choline deficiency or very low dietary choline: 1,000–2,000 mg/day choline (as phosphatidylcholine or bitartrate) for 3–6 months with monitoring of hepatic transaminases and imaging; this is specialist-adjunct therapy, not standalone NAFLD treatment. Weight loss and metabolic management remain primary. For cognitive enhancement trials in healthy adults or mild cognitive impairment, Alpha-GPC at 300–1,200 mg/day (typically 600 mg twice daily) or CDP-choline at 500–2,000 mg/day (typically 1,000 mg once daily or 500 mg twice daily); trial for 3–6 months with subjective and objective cognitive assessment. Alpha-GPC evidence is modestly stronger than CDP-choline for cognitive outcomes, though CDP-choline has more cardiovascular safety data. For homocysteine lowering via betaine, betaine (trimethylglycine) at 3 g twice daily (6 g total) reliably lowers homocysteine by 10–20% (Alfthan 2004). For pyridoxine-unresponsive homocystinuria from CBS deficiency, betaine (Cystadane) at 6 g/day is FDA-approved therapy alongside methionine restriction and cysteine supplementation, under metabolic medicine oversight. For elderly or MCI cognitive support, 600 mg Alpha-GPC once or twice daily plus a standard B-complex is a reasonable evidence-based stack. For athletic or sports-performance cholinergic enhancement, evidence is weak; 500 mg Alpha-GPC pre-workout is commonly used in nootropics community without robust trial support. Monitor for fishy odor at high doses (usually above 1.5–2 g total daily choline) and reduce if significant. Do not exceed 3.5 g/day total from all sources without specific clinical indication and monitoring.
The Advanced Protocol covers specialist-directed high-dose choline or betaine therapy, TPN supplementation, and rare metabolic indications. For long-term total parenteral nutrition (TPN) patients, choline deficiency with fatty liver is nearly universal without supplementation; TPN-compatible choline chloride at 1–4 g/day is standard, with hepatic monitoring. For primary carnitine deficiency with concurrent choline needs, coordinated metabolic medicine protocol. For pyridoxine-unresponsive homocystinuria from CBS deficiency: betaine (Cystadane, FDA-approved as orphan drug) at 6 g/day initially, titrated to homocysteine control, with monitoring of plasma methionine (hypermethionemia with cerebral edema is a documented rare complication). Methionine restriction diet plus cysteine supplementation is standard concurrent therapy. Homocystinuria specialists coordinate this. For cystathionine beta-synthase deficiency with pyridoxine partial response, combined therapy with pyridoxine 100–500 mg/day + betaine 3–6 g/day + methionine restriction may be used. For liver-related conditions like severe fatty liver failure, alcoholic hepatitis, primary biliary cirrhosis, NASH with advanced fibrosis, parenteral or oral phosphatidylcholine or polyunsaturated phosphatidylcholine (PPC) has been studied, with mixed evidence for hepatoprotection; generally specialist-directed with specific clinical monitoring. For stroke recovery, CDP-choline (citicoline) at 2 g/day has been used; ICTUS trial did not show overall benefit but some subgroup analyses and regional uses continue, under neurology oversight. For bipolar disorder mania, Stoll 1996 reported symptom improvement with choline bitartrate 2–7 g/day augmentation of lithium, though subsequent work is limited and this is not standard psychiatric therapy. For traumatic brain injury, CDP-choline has been explored with mixed results. For primary and secondary carnitine-related disorders, carnitine is primary; choline complementary. For trimethylaminuria (FMO3 deficiency), the approach is dietary choline/carnitine restriction plus riboflavin (cofactor for FMO3 that has some activity in partial deficiency) rather than supplementation — betaine and choline supplements should be avoided in TMAU. For very long-chain fatty acid disorders or peroxisomal disorders requiring specialty lipid formulations, choline needs are individualized. The Advanced Protocol is specialist-directed — hepatology, metabolic medicine, psychiatry, neurology — with defined dosing, response monitoring, and recognition of the methionine-hypermethioninemia risk with chronic high-dose betaine. Self-directed gram-range chronic choline or betaine dosing outside these specific indications is not evidence-supported and may exacerbate TMAO concerns for some individuals.
Commonly Stacked With
Choline's stacking logic centers on methylation partnerships, phospholipid synthesis coordination, and cognitive/membrane support pairings. With Folate, choline is the complementary methyl donor that provides the alternative BHMT pathway for homocysteine remethylation, bypassing the folate-B12-dependent methionine synthase reaction. This is why choline deficiency can contribute to NTD risk independent of folate status (Shaw 2004, Carmichael 2010, 20332367) and why both should be considered in prenatal nutrition. A thoughtful pregnancy stack includes 400–800 mcg folate + 450–900 mg choline (AI is 450 mg, but Caudill 2018 trial suggests benefit at 930 mg). Unfortunately most prenatal vitamins contain little or no choline because of formulation size and cost constraints, so supplemental choline alongside prenatal folate is often needed. Choline and Vitamin B12: complementary in the methylation framework; B12 drives the remethylation arm via methionine synthase, choline-betaine drives BHMT, and both support adequate SAMe for downstream methylation. In B12-deficient states, adequate choline can partially compensate for impaired methionine synthase activity via BHMT. Choline and Vitamin B6: B6 supports the transsulfuration arm of homocysteine disposal; choline-betaine supports the BHMT remethylation; together they cover alternative homocysteine handling pathways. For comprehensive homocysteine-lowering or methylation support, stacks combining folate + B12 + B6 + betaine have been used. Choline and Glycine: glycine and serine are substrates in one-carbon metabolism; dimethylglycine (the byproduct of BHMT's betaine methyl donation) undergoes further oxidation to sarcosine and glycine via DMGDH and SARDH, linking betaine metabolism back to glycine. The choline-betaine-BHMT-glycine axis is interconnected with folate one-carbon metabolism. Choline and Omega-3 fatty acids: DHA incorporates into membrane phospholipids primarily as phosphatidylcholine-DHA, and choline availability supports DHA incorporation into neural and retinal membranes. The pregnancy stack of omega-3 + choline + folate addresses membrane lipid synthesis and methylation simultaneously for fetal neurodevelopment. Choline and Alpha-Lipoic Acid: no direct interaction at standard doses. Choline and CoQ10: complementary mitochondrial and membrane support; no direct interaction. Choline and Magnesium: no direct interaction. Choline and Iron: no direct interaction. Choline and Creatine: both support methylation economy — creatine synthesis requires SAMe (consuming up to 50% of methyl groups in some analyses), and adequate choline-betaine provides methyl substrate supply. The theoretical synergy between creatine and choline for cognitive or athletic purposes is attractive but not strongly supported by outcome trials. Choline and caffeine/stimulants: cholinergic and dopaminergic/adenosine pathways are complementary; anecdotal reports of Alpha-GPC + caffeine or CDP-choline + caffeine as a cognitive stack are common in the nootropics subculture, with modest trial support. Choline and cholinesterase inhibitors (donepezil, rivastigmine, galantamine for Alzheimer's): Alpha-GPC or CDP-choline supplementation alongside these medications provides potentially additive but modest cognitive effects; specialist-directed. Choline and racetams (piracetam, aniracetam, pramiracetam): the nootropics community pairs racetams with Alpha-GPC or CDP-choline on the theory that racetams enhance cholinergic neurotransmission and benefit from adequate choline substrate; modest trial evidence, mostly in MCI and cognitive impairment rather than healthy adults. Choline and L-carnitine: shared TMAO biology — both can elevate TMAO via gut bacterial TMA production; for individuals concerned about TMAO, combining high doses of both warrants consideration. Choline and betaine: betaine is the oxidation product of choline via choline dehydrogenase; supplementing both simultaneously is reasonable for methylation support, with betaine emphasized if homocysteine lowering is the goal and choline emphasized if membrane phospholipid support is primary. Betaine 3–6 g/day is used for pyridoxine-unresponsive homocystinuria as FDA-approved therapy (Cystadane). Timing: choline can be taken any time of day; food doesn't significantly affect absorption. Morning dosing is common for cognitive-enhancement use; with food for GI tolerance of higher doses. Split dosing for high-dose indications to minimize GI upset. The cleanest stacking synthesis: choline + folate for pregnancy methylation and NTD prevention; choline-betaine + folate + B12 + B6 for comprehensive homocysteine lowering; Alpha-GPC + caffeine for cognitive stacking; choline + DHA/omega-3 for membrane synthesis particularly in pregnancy and pediatric neurodevelopment.
Side Effects & Safety
Contraindications
Choline is generally very safe and has essentially no absolute contraindications at AI-range intake, but several contexts warrant specific caution. Trimethylaminuria (TMAU, fish odor syndrome) from FMO3 deficiency is a relative contraindication for high-dose choline, phosphatidylcholine, L-carnitine, and betaine supplementation — affected individuals cannot oxidize trimethylamine (TMA) to odorless TMAO, and dietary management reduces symptoms via limiting choline, carnitine, and related precursor intake. Supplementation would worsen body odor in these patients. Genetic testing can confirm FMO3 variants. Homocystinuria patients on chronic betaine therapy require plasma methionine monitoring due to the documented risk of hypermethionemia with cerebral edema at very high doses over extended periods (Yaghmai 2002). Bipolar disorder patients: high-dose choline bitartrate (multigram) has been reported in rare cases to trigger or worsen depressive symptoms (despite the Stoll 1996 mania findings), possibly via cholinergic-adrenergic balance; monitor mood on any psychiatric supplementation. Parkinson disease: no strong contraindication, though theoretical acetylcholine-dopamine balance considerations suggest Parkinson patients should discuss supplementation with neurology; some reports of worsening symptoms on high-dose choline in untreated or undertreated Parkinson patients. Myasthenia gravis: theoretical concern that choline or Alpha-GPC could augment cholinergic signaling and potentially affect disease course or medication dosing; discuss with neurology before supplementation. Active ulcerative colitis flares and severe Crohn's disease with active diarrhea: high-dose phosphatidylcholine and Alpha-GPC can worsen GI symptoms; use smaller doses or pause during flares. Pregnancy: choline is essential and recommended at or above AI through pregnancy and lactation; no contraindication. The TMAO-CV risk hypothesis warrants moderate caution for individuals with established cardiovascular disease or elevated CV risk: while not a strict contraindication, choosing moderate choline intake (meeting AI, but not multi-gram supplementation) and pairing with prebiotic/probiotic interventions that shift gut microbiome toward lower TMA production may be prudent. No clear contraindication for CV patients at AI-range intake. Anticholinergic medications (tricyclic antidepressants, scopolamine, atropine, many antipsychotics, some antihistamines): pharmacodynamic counter-action may reduce medication efficacy; generally not clinically significant at standard doses. Cholinergic medications (pilocarpine, physostigmine, donepezil, rivastigmine, galantamine): choline supplementation is usually complementary and not contraindicated, though specific dose coordination with prescribing neurologist or psychiatrist is reasonable. Drug interactions overall are generally mild at typical supplemental doses. Hepatic encephalopathy: theoretical concern with ammonia-related neurotoxicity; monitor in cirrhotic patients on choline or betaine. Renal impairment: no specific contraindication at AI-range; high-dose betaine in severe renal impairment may alter methylation economy. Children: RDA-range is safe and important; high-dose supplementation should be pediatrician-directed. Elderly: choline needs may be slightly higher due to increased requirements of homocysteine remethylation and age-related changes; RDA-range is safe. Drug interactions warranting attention: anticholinergics (pharmacodynamic counter-action), cholinesterase inhibitors (complementary), methotrexate (complementary methylation considerations), and specific antiarrhythmics with cholinergic modulation. Overall choline is one of the safest and most essential nutrients at AI-to-moderate supplementation, with TMAU patients being the primary exception for high-dose use. This is general educational content, not medical advice.
Additional Notes
Dosing choline requires distinguishing the many available forms and recognizing that different products provide very different amounts of elemental choline. Choline bitartrate is approximately 40% choline by mass (one 500 mg choline bitartrate tablet = ~200 mg choline). Choline chloride is approximately 75% choline by mass. Phosphatidylcholine (as PC or from lecithin) contains approximately 13% choline by mass (2 g lecithin = ~260 mg choline from PC fraction, though most lecithin supplements contain varying percentages of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine). Sunflower lecithin is typically 20–30% phosphatidylcholine by mass. Alpha-GPC is approximately 40% choline by mass and has better CNS penetration than choline bitartrate, at 3–5× the cost. CDP-choline (citicoline) is approximately 18% choline by mass plus 16% cytidine. Betaine (trimethylglycine, TMG) is not directly choline but is the oxidation product of choline and provides methyl groups via BHMT; it is not a choline substitute for membrane or acetylcholine needs but does provide methylation equivalents. Common dosing: AI adult men 550 mg/day, adult women 425 mg/day (as total from diet + supplement); pregnancy 450 mg/day; lactation 550 mg/day; UL adult 3.5 g/day total from all sources. For supplementation closing AI gaps: 250–500 mg/day choline (as bitartrate or equivalent), typically 500–1,250 mg choline bitartrate or 2–4 g sunflower lecithin. For pregnancy per Caudill 2018 evidence: 900–1,000 mg/day total choline (from food + supplement), which for most pregnant women means adding 450–900 mg choline from supplement. For Alpha-GPC cognitive enhancement: 300–1,200 mg/day, typically 600 mg twice daily (providing ~240 mg choline). For CDP-choline cognitive support: 500–2,000 mg/day (providing ~90–360 mg choline plus cytidine). For betaine homocysteine lowering: 3 g twice daily (6 g total); for homocystinuria 6 g/day (Cystadane prescribing). For NAFLD in deficient patients: 1,000–2,000 mg/day choline. Take with or without food; absorption is good either way. Split high-dose supplementation across the day to minimize peak-dose GI effects and fishy odor. Lab monitoring: plasma free choline (less commonly measured; reference approximately 7–20 μmol/L), plasma phosphatidylcholine (often measured as part of lipidomic panels), urinary TMAO (emerging marker for gut TMA production and CV risk assessment), homocysteine (for betaine-treated patients), and plasma methionine for patients on chronic high-dose betaine (hypermethioninemia surveillance). For general supplementation, lab monitoring is usually unnecessary beyond routine labs. Form selection: choline bitartrate is the cheap default appropriate for most closing-the-gap supplementation; sunflower lecithin provides PC and additional phospholipids useful for membrane support; Alpha-GPC and CDP-choline are premium forms with modest cognitive-enhancement trial support and higher cost; betaine is specifically used for homocysteine lowering or homocystinuria rather than as a general choline substitute.
Frequently Asked Questions
What is the recommended Choline dosage?
Dosage for Choline varies by protocol. Consult a qualified healthcare provider.
How often should I take Choline?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Choline need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Choline side effects?
Choline at dietary intakes and supplementation up to the UL (3.5 g/day) is generally well tolerated with a modest side effect profile. Acute high-dose choline (above 7.5 g/day in some studies) can produce a fishy body odor from increased trimethylamine production by gut bacteria that isn't fully oxidized in the liver, along with nausea, sweating, diarrhea, and hypotension — this "fish malodor syndrome" is the major dose-limiting side effect and reverses within days of dose reduction. Trimethylaminuria (TMAU) is a genetic syndrome of flavin-containing monooxygenase 3 (FMO3) deficiency that produces persistent fish malodor from inability to oxidize trimethylamine to odorless TMAO; these patients should avoid high-dose choline and related precursors (carnitine, betaine) as dietary management reduces symptoms. Beyond odor issues, choline is well tolerated with rare GI complaints, mild hypotension at high doses, and occasional sweating at very high doses. Phosphatidylcholine (lecithin) is generally well tolerated even at high doses, though GI discomfort and oily stools can occur with multi-gram daily intake. Alpha-GPC and CDP-choline have similar tolerability profiles with occasional reports of headache, dizziness, and GI upset at high doses. Betaine at therapeutic doses (6 g/day for homocystinuria) has been associated with hypermethionemia (elevated plasma methionine) with cerebral edema risk in rare cases, warranting monitoring of plasma methionine in long-term betaine therapy. The major debated concern with high-choline intake is the TMAO (trimethylamine N-oxide) hypothesis for cardiovascular risk. Hazen and colleagues showed that gut bacteria convert choline, phosphatidylcholine, and L-carnitine to trimethylamine (TMA), which is absorbed and hepatically oxidized to TMAO; elevated TMAO has been associated with CV risk in observational cohorts. The concern is that high-dose choline supplementation (above AI) could elevate TMAO and theoretically increase CV risk. Counter-arguments include: (1) the TMAO association is modest in magnitude and its causality is debated; (2) the association depends heavily on gut microbiome composition and varies widely between individuals; (3) major food sources of choline (egg yolks) have been exonerated in most prospective CV studies; (4) dietary factors that elevate TMAO don't cleanly correlate with CV outcomes. The practical position is that choline supplementation to meet the AI is reasonable and generally safe; supra-AI supplementation for specific indications (pregnancy per Caudill 2018, cognitive enhancement, NAFLD in deficient patients) is reasonable but not unlimited; multi-gram chronic choline should have a specific indication. Individuals with TMAU should avoid high-dose choline and related compounds. Individuals with elevated CV risk and known high TMAO might consider moderation of high-choline foods and supplements, though the evidence for this specific intervention is limited. Drug interactions: choline doesn't have major prescription drug interactions at typical supplemental doses. Parasympathomimetic medications (pilocarpine, cholinergic agents for glaucoma, myasthenia gravis treatment) could theoretically be enhanced by high-dose choline, though clinical significance is generally minimal. Anticholinergic medications (scopolamine, atropine, tricyclic antidepressants, many antipsychotics, some antihistamines) work by blocking acetylcholine receptors and are not meaningfully reversed by choline supplementation. Alzheimer's medications that inhibit acetylcholinesterase (donepezil, rivastigmine, galantamine) work by slowing ACh breakdown; choline supplementation in addition provides potentially additive but modest effect. Methotrexate interactions are not significant. Betaine in homocystinuria patients requires methionine monitoring. The cleanest safety summary: choline is well-tolerated at AI and moderate supra-AI intakes; fishy odor and GI discomfort at very high doses (>7.5 g); TMAO concerns are real but likely not prohibitive at sensible supplemental doses; TMAU patients should avoid high choline intake; homocystinuria patients on betaine need methionine monitoring.
Where can I buy Choline?
Visit our vendor directory to find trusted sources for Choline.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
